missing translation for 'onlineSavingsMsg'
Learn More

CLK3 (M07A), Mouse anti-Human, Clone: 7D6, Abnova™

Mouse monoclonal antibody raised against a partial recombinant CLK3.

Brand:  Abnova H00001198-M07A.200uL

Product Code. 16186424

  • 349.00 € / 200µL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

This gene encodes a protein belonging to the serine/threonine type protein kinase family. This protein is a nuclear dual-specificity kinase that regulates the intranuclear distribution of the serine/arginine-rich (SR) family of splicing factors. Two transcript variants encoding different isoforms have been found for this gene. Related pseudogenes are located on chromosomes 1 and 9. [provided by RefSeq

Sequence: YPSRREPPPRRSRSRSHDRLPYQRRYRERRDSDTYRCEERSPSFGEDYYGPSRSRHRRRSRERGPYRTRKHAHHCHKRRTRSCSSASSRSQQSSKRSSRSV
Specifications

Specifications

CLK3
Monoclonal
Unconjugated
ascites with no preservative
BC002555
CLK3
CLK3 (AAH02555, 36 a.a. ∼ 136 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
RUO
1198
Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Ascites
ELISA, Western Blot
7D6
Mouse monoclonal antibody raised against a partial recombinant CLK3.
CLK3
FLJ22858/PHCLK3/PHCLK3/152
Mouse
200 μL
Primary
Human
Antibody
IgG2b κ
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.